New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

The study enrolled 523 patients with untreated CLL, randomly assigning them to receive either MRD-driven ibrutinib-venetoclax therapy or standard FCR. After a median follow-up of 43.7 months ...

The molecular mechanisms underlying resistance to therapy in Chronic lymphocytic leukemia (CLL) remain to be explored. Here, the authors perform multi-omics analysis in a mouse model of ibrutinib ...

Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

It can be difficult to find out that you have acute lymphoblastic leukaemia (ALL). It’s normal to feel angry, sad, upset and shocked. You might worry about what will happen and how you will cope.

The start of NX-5948's CLL registrational trial in 2025 As of ... starting with warm Autoimmune Hemolytic Anemia (wAIHA), represents a significant growth opportunity. The autoimmune disease ...

Helen Jackson's toddler, misdiagnosed with flu, was later found to have acute lymphoblastic leukemia after her condition worsened. Gracie, 2, underwent immediate treatment, including chemotherapy ...